Yifan He, Li Xu, Xiaojing Pei, Yinmao Dong, Xiangliang Yang
{"title":"Preparation of Polydeoxyribonucleotide Nanoliposomes and their Applicability to Cosmetic Formulations.","authors":"Yifan He, Li Xu, Xiaojing Pei, Yinmao Dong, Xiangliang Yang","doi":"10.2174/0113892010353418250218064202","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>The use of polydeoxyribonucleotide (PDRN) in promoting tissue repair and anti-aging has been hindered by several challenges, including its large molecular weight, susceptibility to decomposition, low bioavailability, and poor stability and skin permeability. Liposome formulation technology has emerged as a promising method in cosmetics, enhancing the penetration and protection of active ingredients.</p><p><strong>Method: </strong>In this study, a PDRN-loaded nanoliposomal (PDRN-NL) formulation, which exhibited an average particle size of 125 ± 1 nm, a polydispersity index (PDI) of 0.12 ± 0.02, a zeta potential of -52.6 ± 0.8 mV, and an encapsulation efficiency of 81.3%. The stability of the PDRN-NL and its formulations was assessed using the Turbiscan Lab stability analyzer, which predicted a shelf life of up to three years. Furthermore, the in vitro permeability of the PDRN-NL was evaluated using the Franz diffusion cell method.</p><p><strong>Results: </strong>Results indicated that the cumulative skin permeation of PDRN-NL over 24 hours was 1.22 times higher than that of free PDRN, with skin retention of PDRN-NL being 1.40 times greater. The in vitro release studies demonstrated that liposomal encapsulation not only enhanced permeability but also provided a sustained-release effect and improved stability of PDRN.</p><p><strong>Conclusion: </strong>Overall, the properties of liposome-encapsulated PDRN were significantly enhanced, presenting a novel solution for the incorporation of PDRN in the development of skincare products.</p>","PeriodicalId":10881,"journal":{"name":"Current pharmaceutical biotechnology","volume":" ","pages":""},"PeriodicalIF":2.2000,"publicationDate":"2025-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current pharmaceutical biotechnology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0113892010353418250218064202","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: The use of polydeoxyribonucleotide (PDRN) in promoting tissue repair and anti-aging has been hindered by several challenges, including its large molecular weight, susceptibility to decomposition, low bioavailability, and poor stability and skin permeability. Liposome formulation technology has emerged as a promising method in cosmetics, enhancing the penetration and protection of active ingredients.
Method: In this study, a PDRN-loaded nanoliposomal (PDRN-NL) formulation, which exhibited an average particle size of 125 ± 1 nm, a polydispersity index (PDI) of 0.12 ± 0.02, a zeta potential of -52.6 ± 0.8 mV, and an encapsulation efficiency of 81.3%. The stability of the PDRN-NL and its formulations was assessed using the Turbiscan Lab stability analyzer, which predicted a shelf life of up to three years. Furthermore, the in vitro permeability of the PDRN-NL was evaluated using the Franz diffusion cell method.
Results: Results indicated that the cumulative skin permeation of PDRN-NL over 24 hours was 1.22 times higher than that of free PDRN, with skin retention of PDRN-NL being 1.40 times greater. The in vitro release studies demonstrated that liposomal encapsulation not only enhanced permeability but also provided a sustained-release effect and improved stability of PDRN.
Conclusion: Overall, the properties of liposome-encapsulated PDRN were significantly enhanced, presenting a novel solution for the incorporation of PDRN in the development of skincare products.
期刊介绍:
Current Pharmaceutical Biotechnology aims to cover all the latest and outstanding developments in Pharmaceutical Biotechnology. Each issue of the journal includes timely in-depth reviews, original research articles and letters written by leaders in the field, covering a range of current topics in scientific areas of Pharmaceutical Biotechnology. Invited and unsolicited review articles are welcome. The journal encourages contributions describing research at the interface of drug discovery and pharmacological applications, involving in vitro investigations and pre-clinical or clinical studies. Scientific areas within the scope of the journal include pharmaceutical chemistry, biochemistry and genetics, molecular and cellular biology, and polymer and materials sciences as they relate to pharmaceutical science and biotechnology. In addition, the journal also considers comprehensive studies and research advances pertaining food chemistry with pharmaceutical implication. Areas of interest include:
DNA/protein engineering and processing
Synthetic biotechnology
Omics (genomics, proteomics, metabolomics and systems biology)
Therapeutic biotechnology (gene therapy, peptide inhibitors, enzymes)
Drug delivery and targeting
Nanobiotechnology
Molecular pharmaceutics and molecular pharmacology
Analytical biotechnology (biosensing, advanced technology for detection of bioanalytes)
Pharmacokinetics and pharmacodynamics
Applied Microbiology
Bioinformatics (computational biopharmaceutics and modeling)
Environmental biotechnology
Regenerative medicine (stem cells, tissue engineering and biomaterials)
Translational immunology (cell therapies, antibody engineering, xenotransplantation)
Industrial bioprocesses for drug production and development
Biosafety
Biotech ethics
Special Issues devoted to crucial topics, providing the latest comprehensive information on cutting-edge areas of research and technological advances, are welcome.
Current Pharmaceutical Biotechnology is an essential journal for academic, clinical, government and pharmaceutical scientists who wish to be kept informed and up-to-date with the latest and most important developments.